Defining optimal treatment for recurrent Clostridioides difficile infection (OpTION study): A randomized, double-blind comparison of three antibiotic regimens for patients with a first or second recurrence

Stuart Johnson,Dale N Gerding,Xue Li,Domenic J Reda,Curtis J Donskey,Kalpana Gupta,Matthew Bidwell Goetz, Michael W Climo, Fred M Gordin, Robert Ringer, Neil Johnson, Michelle Johnson, Lawrence A Calais, Alexa M Goldberg, Ling Ge, Tamara Haegerich

Contemporary Clinical Trials（2022）

引用 1|浏览3

暂无评分

摘要

•Treatment recommendations for recurrent C. difficile vary among guidelines.•Current recommendations are also based on low-quality evidence.•CSP 596 will determine comparative efficacy of FDX, VAN, and VAN-T/P, informing care.•Novel methods included a pilot phase and modifications to reduce recruitment barriers.•Protocol modifications addressed evolving CDI management and the COVID-19 pandemic.

查看译文

关键词

C. difficile,Recurrence,Clinical trial,Study design,Clinical treatment,Veterans

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要